Mahmut TÖBÜ, Filiz VURAL, Murat TOMBULOĞLU, Ayşe UYSAL, Fahri ŞAHİN, Güray SAYDAM, Püsem PATIR, Hatice Demet ÜNAL, Nur SOYER, Mustafa DURAN, Raika DURUSOY

Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience

Background/aim: In Turkey, lenalidomide plus dexamethasone (RD) has been used to treat relapsed/refractory multiple myeloma(RRMM) since 2010. This retrospective, single-center study evaluated the efficacy and tolerability of RD in patients with RRMMbetween October 2010 and June 2016.Materials and methods: Patients’ records were reviewed, and overall (OS) and progression-free survival (PFS) were assessed.Results: One hundred and twenty patients (71 males; 59.2%) were included in the study. The median number of prior lines of treatmentwas one (1–4); 72 patients (60.0%) received RD as second-line therapy and 51 patients (42.5%) had previously undergone autologousstem cell transplantation (ASCT). The overall response rate was 72.5%, with 19% of these patients achieving a complete response. Themedian length of follow-up and duration of response to RD was 14 months and 19 months, respectively. Median OS and PFS were 32and 21 months, respectively. Prior ASCT, an overall response, and treatment with RD for >12 cycles were identified as independentprognostic factors for OS and PFS. Adverse events (AEs) occurred in 69 (57.5%) and 14 patients (11.7%) discontinued treatment dueto AEs.Conclusions: We found RD to be safe, well tolerated, and effective in RRMM in everyday clinical practice in Turkey.

PDF

___

Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2016; 91: 101-119.
Rajkumar SV. Myeloma today: disease definitions and treatment advances. Am J Hematol 2016; 91: 90-100.
Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122-1128.
Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Eng J Med 2007; 357: 2123- 2132.
Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, ChananKhan AA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.
Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23: 2147-2152.
Katodritou E, Vadikolia C, Lalagianni C, Kotsopoulou M, Papageorgiou G, Kyrtsonis MC, Matsouka P, Giannakoulas N, Kyriakou D, Karras G et al. “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. Ann Hematol 2014; 93: 129-139.
João C, Coelho I, Costa C, Esteves S, Lucio P. Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma- -real life experience of a tertiary cancer center. Ann Hematol 2015; 94: 97-105.
Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
Mahajan R. Real world data: additional source for making clinical decisions. Int J Appl Basic Med Res 2015; 5: 82.
Annemans L, Aristides M, Kubin M. Real Life Data: A Growing Need. ISPOR Connections. Lawrenceville, NJ, USA: International Society For Pharmacoeconomics and Outcomes Research; 2007.
Alegre A, Oriol-Rocafiguera A, Garcia-Larana J, Mateos MV, Sureda A, Martinez-Chamorro C, Cibeira MT, Aguado B, Knight R, Rosettani B. Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. Leuk Lymphoma 2012; 53: 1714-1721.
Kneppers E, Lokhorst HM, Eeltink CM, Huls G, Kersten MJ, Koedam J, Minnema MC, van Oers MH, Raymakers RA, Schaafsma MR et al. Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clin Lymphoma Myeloma Leuk 2010; 10: 138- 143.
Tuglular Firatli AT, Pehlivan M, Sari HI, Ayyildiz MO, Saydam G, Sonmez M, Kalayoglu Besisik S, Ozgur G, Gurkan E, Kaynar L et al. Post-authorization safety of lenalidomide + dexamethasone in patients with relapsed/refractory multiple myeloma: early safety report of Turkish PASS study. In: Cools J, Malcovati L, editors. Proceedings of the 20th Congress of the European Hematology Association; 11–14 June, 2015. Vienna, Austria: European Hematology Association; 2015. p. 734.
Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, Facon T, Olesnyckyj M, Yu Z, Zeldis JB et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009; 82: 426-432.
Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, Morgan GJ. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012; 119: 2764-2767.
Dimopoulos MA, Swern AS, Li JS, Hussein M, Weiss L, Nagarwala Y, Baz R. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J 2014; 4: e257.